language Türkçe
Article 2023 · 20 citations

Lipoic Acid Conjugated Boron Hybrids Enhance Wound Healing and Antimicrobial Processes

Turkez, Hasan, Yildirim, Ozge Caglar, Oner, Sena, Kadi, Abdurrahim, Mete, Abdulkadir, Arslan, Mehmet Enes, Sahin, Irfan Oguz, Yapca, Omer Erkan, Mardinoglu, Adil

Abstract

Complications of chronic non-healing wounds led to the emergence of nanotechnology-based therapies to enhance healing, facilitate tissue repair, and prevent wound-related complications like infections. Here, we design alpha lipoic acid (ALA) conjugated hexagonal boron nitride (hBN) and boron carbide (B4C) nanoparticles (NPs) to enhance wound healing in human dermal fibroblast (HDFa) cell culture and characterize its antimicrobial properties against Staphylococcus aureus (S. aureus, gram positive) and Escherichia coli (E. coli, gram negative) bacterial strains. ALA molecules are integrated onto hBN and C4B NPs through esterification procedure, and molecular characterizations are performed by using transmission electron microscopy (TEM), Fourier transform infrared spectroscopy (FTIR), and UV-vis spectroscopy. Wound healing and antimicrobial properties are investigated via the use of cell viability assays, scratch test, oxidative stress, and antimicrobial activity assays. Based on our analysis, we observe that ALA-conjugated hBN NPs have the highest wound-healing feature and antimicrobial activity compared to ALA-B4C. On the other hand, hBN, ALA-B4C, and ALA compounds showed promising regenerative and antimicrobial properties. Also, we find that ALA conjugation enhances wound healing and antimicrobial potency of hBN and B4C NPs. We conclude that the ALA-hBN conjugate is a potential candidate to stimulate regeneration process for injuries.

Keywords
wound healing antimicrobial effect nanoparticles lipoic acid boron nitride boron carbide BORIC-ACID EXTRACELLULAR-MATRIX ANTIOXIDANT DERIVATIVES RELEASE PVA
WoS Categories
Pharmacology & Pharmacy
Sustainable Development Goals
Citation
Journal
PHARMACEUTICS
Year
2023
Volume
15
Issue
1
eISSN
1999-4923
DOI
10.3390/pharmaceutics15010149
WoS UID
WOS:000916405800001
Open via DOI